"omega-N-Methylarginine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive inhibitor of nitric oxide synthetase.
| Descriptor ID |
D019323
|
| MeSH Number(s) |
D12.125.068.050.650 D12.125.095.104.650 D12.125.142.087.500
|
| Concept/Terms |
omega-N-Methylarginine- omega-N-Methylarginine
- omega N Methylarginine
- NG-Monomethyl-L-Arginine
- NG Monomethyl L Arginine
- L-NMMA
- L-Monomethylarginine
- L Monomethylarginine
- N(G)-Monomethylarginine
- D-NMMA
- N(G)-Monomethyl-D-Arginine
- N(omega)-Monomethyl-L-Arginine
- L-NG-Monomethyl Arginine
- Arginine, L-NG-Monomethyl
- L NG Monomethyl Arginine
- N(G)-Methylarginine
|
Below are MeSH descriptors whose meaning is more general than "omega-N-Methylarginine".
Below are MeSH descriptors whose meaning is more specific than "omega-N-Methylarginine".
This graph shows the total number of publications written about "omega-N-Methylarginine" by people in this website by year, and whether "omega-N-Methylarginine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "omega-N-Methylarginine" by people in Profiles.
-
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021 12 15; 13(624):eabj5070.
-
Role of RPL39 in Metaplastic Breast Cancer. J Natl Cancer Inst. 2017 06; 109(6).
-
Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother. 2011 Jun; 34(5):419-27.
-
Distribution of NOS isoforms in a porcine endotoxin shock model. Shock. 2008 Jun; 29(6):692-702.
-
Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. J Immunother. 2008 May; 31(4):325-33.
-
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. 2007 May; 28(9):1109-16.
-
Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J Cereb Blood Flow Metab. 2007 Feb; 27(2):282-92.
-
Mechanisms of beta-adrenergic receptor-mediated venodilation in humans. Clin Pharmacol Ther. 2004 Jan; 75(1):49-59.
-
Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan; 32(1):13-20.
-
Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003 Oct 01; 35(7):790-6.